NXE0 Stock Overview A clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system and other disorders. More details
Risk Analysis + 2 more risks
See All Risk Checks Capture your thoughts, links and company narrative
Seelos Therapeutics, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Seelos Therapeutics Historical stock prices Current Share Price US$2.00 52 Week High US$288.96 52 Week Low US$2.00 Beta 1.89 1 Month Change 0% 3 Month Change n/a 1 Year Change -99.31% 3 Year Change -99.50% 5 Year Change -99.43% Change since IPO -99.76%
Recent News & Updates
Seelos Therapeutics, Inc. announced delayed 10-Q filing Nov 24 Seelos Therapeutics, Inc. Filed for Bankruptcy Nov 18
Seelos Therapeutics, Inc.(OTCPK:SEEL) dropped from S&P TMI Index Oct 18
Seelos Therapeutics, Inc.(OTCPK:SEEL) dropped from NASDAQ Composite Index Oct 16 Seelos Therapeutics Announces Notice of Delisting from Nasdaq and Transfer of Listing to Over-the-Counter Market Oct 15
Seelos Therapeutics, Inc. has filed a Follow-on Equity Offering. Sep 25
See more updates
Seelos Therapeutics, Inc. announced delayed 10-Q filing Nov 24 Seelos Therapeutics, Inc. Filed for Bankruptcy Nov 18
Seelos Therapeutics, Inc.(OTCPK:SEEL) dropped from S&P TMI Index Oct 18
Seelos Therapeutics, Inc.(OTCPK:SEEL) dropped from NASDAQ Composite Index Oct 16 Seelos Therapeutics Announces Notice of Delisting from Nasdaq and Transfer of Listing to Over-the-Counter Market Oct 15
Seelos Therapeutics, Inc. has filed a Follow-on Equity Offering. Sep 25
Seelos Therapeutics, Inc., Annual General Meeting, Sep 27, 2024 Aug 12 Seelos Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $1.136948 million.
Seelos Therapeutics Announces 1-for-8 Reverse Stock Split to Regain Compliance with the Minimum Bid Price Requirement of $1.00 Per Share of Common Stock for Continued Listing on the Nasdaq Capital Market May 15 Nasdaq to Delist Common Stock of Seelos Therapeutics May 04
Seelos Therapeutics, Inc. Announces Appointment of Richard Pascoe as Chairman of the Board of Directors Apr 30
Seelos Therapeutics, Inc. Provides Update on Top-Line Results from its Amyotrophic Lateral Sclerosis Study with SLS-005 (IV Trehalose) Mar 20 Seelos Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $4.000001 million. Jan 31
Seelos Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $4.000001 million. Jan 26
Seelos Therapeutics, Inc. Announces Receipt of Minutes from its End of Phase II Meeting with the United States Food and Drug Administration Highlighting Modifications to the Primary and Secondary Endpoints of its Phase II Study of SLS-002 Jan 22
Founder recently bought €92k worth of stock Dec 04
New major risk - Market cap size Nov 30 Seelos Therapeutics, Inc. has completed a Follow-on Equity Offering. Nov 30
Seelos Therapeutics, Inc. has filed a Follow-on Equity Offering.
New major risk - Shareholder dilution Nov 20
New major risk - Revenue and earnings growth Nov 17
Seelos Therapeutics Receives Non-Compliance Notice from Nasdaq Regarding Non-Compliance with Minimum Bid Price Requirement for Continued Listing on the Nasdaq Capital Market Under Nasdaq Listing Rule 5550(a)(2) Nov 05
Seelos Therapeutics Receives Non-Compliance Notice From Nasdaq Nov 04
Seelos Therapeutics, Inc. Announces Top Line Results from SLS-002 Phase II Study in Adults with Major Depressive Disorder at Imminent Risk of Suicide Sep 21
Seelos Therapeutics, Inc. Announces the Close of Enrollment of Its Registration Directed Study of Sls-002 (Intranasal Racemic Ketamine) for Acute Suicidal Ideation and Behavior (Asib) in Adults with Major Depressive Disorder (MDD) Jun 23
Listing Qualifications Staff of Nasdaq Provides Notice to Seelos Therapeutics for Not Regain Compliance with Rule 5550(a)(2) and Not Eligible for Second 180 Calendar Day Compliance Period May 29
No longer forecast to breakeven Mar 11
Seelos Therapeutics Announces Completion of Enrollment of its Phase II/III Trial of SLS-005 in Amyotrophic Lateral Sclerosis on the HEALEY ALS Platform Feb 14
Seelos Therapeutics Doses First Patients in an Ethnobridging Study with Sls-002 (Intranasal Racemic Ketamine) Feb 07
Seelos Therapeutics, Inc. Announces Data Demonstrating Downregulation of Alpha Synuclein in an In Vivo Gene Therapy Study of SLS-004 Utilizing CRISPR-dCas9 in Parkinson's Disease Dec 16
Seelos Therapeutics Receives Written Notice of Non-Compliance from Nasdaq Nov 24
Seelos Therapeutics Doses First Patient in A Registrational Phase II/III Study of SLS-005 in Spinocerebellar Ataxia Oct 26
Seelos Therapeutics Inc. Receives A Research and Development Grant from the Michael J. Fox Foundation for Parkinson's Research for SLS-004 Aug 25
Seelos Therapeutics, Inc. Announces Data Demonstrating Statistically Significant Downregulation of mRNA and Reduction of Alpha Synuclein in Vitro Gene Therapy Study Jun 10
Seelos Therapeutics, Inc. Receives Notice of Allowance in U.S. for an Additional Patent for SLS-007 May 19
Seelos Therapeutics Receives Written Notice from The Nasdaq Stock Market LLC Regarding Minimum Bid Price Requirement Apr 23
Seelos Therapeutics, Inc., Annual General Meeting, May 20, 2022 Apr 13
Founder recently bought €51k worth of stock Apr 02
Seelos Therapeutics, Inc. Announces Dosing of the First Participants in a Registrational Phase II/III Trial of SLS-005 in Amyotrophic Lateral Sclerosis on the HEALEY ALS Platform Mar 01
Seelos Therapeutics, Inc. announced that it has received $20 million in funding from The Lind Partners, LLC Nov 25
High number of new and inexperienced directors Nov 01
High number of new and inexperienced directors Oct 02
High number of new and inexperienced directors Sep 13
Director Judith Dunn has left the company Sep 08
Seelos Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $60.000004 million. May 22
Seelos Therapeutics, Inc. Announces Positive Data from the Open-Label Study of SLS-002 May 18
Seelos Therapeutics Announces Completion of Open-Label Patient Enrollment of Proof of Concept Study of SLS-002 (Intranasal Racemic Ketamine) for Acute Suicidal Ideation and Behavior in Patients with Major Depressive Disorder Mar 07
Seelos Therapeutics Announces Amendment of SLS-002 Agreement to Repurchase a Significant Portion of Royalties for SLS-002 (Intranasal Racemic Ketamine Program) Feb 19
New 90-day high: €3.20 Feb 12
New 90-day high: €1.60 Jan 23
Seelos Therapeutics, Inc. Announces Dosing of the First Patients in its Registrational Proof of Concept Study of SLS-002 (Intranasal Racemic Ketamine) for Acute Suicidal Ideation and Behavior Jan 16
Seelos Therapeutics Regains Compliance with Minimum Bid Price Requirement Jan 14
New 90-day high: €1.33 Dec 23
Seelos Therapeutics, Inc. announced that it has received $10 million in funding from The Lind Partners, LLC Dec 15
New 90-day high: €0.93 Dec 01
Revenue in line with expectations Nov 14
Seelos Therapeutics, Inc. Announces Sponsored Research Agreement with Duke University for Gene Therapy Studies of SLS-004 in Parkinson's Disease Sep 24
Seelos Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $7.00335 million. Sep 20
New 90-day low - €0.56 Sep 05
New 90-day low - €0.70 Aug 19 Seelos Therapeutics, Inc.(NasdaqCM:SEEL) dropped from Russell Microcap Value Index Shareholder Returns NXE0 DE Pharmaceuticals DE Market 7D 0% 1.2% 1.5% 1Y -99.3% -13.4% 12.6%
See full shareholder returns
Return vs Market: NXE0 underperformed the German Market which returned -0.8% over the past year.
Price Volatility Is NXE0's price volatile compared to industry and market? NXE0 volatility NXE0 Average Weekly Movement n/a Pharmaceuticals Industry Average Movement 5.4% Market Average Movement 4.8% 10% most volatile stocks in DE Market 11.1% 10% least volatile stocks in DE Market 2.3%
Stable Share Price: NXE0 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine NXE0's volatility change over the past year.
About the Company Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system and other disorders. The company’s lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-004, an gene therapy targeting gene and alpha synuclein; SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; SLS-007, a peptidic inhibitor for NACore Parkinson disease; and SLS-009, a protein targeted autophagy for Alzheimer disease. Seelos Therapeutics, Inc. was founded in 2016 and is headquartered in New York, New York.
Show more Seelos Therapeutics, Inc. Fundamentals Summary How do Seelos Therapeutics's earnings and revenue compare to its market cap? NXE0 fundamental statistics Market cap €665.26k Earnings (TTM ) -€24.82m Revenue (TTM ) €1.81m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) NXE0 income statement (TTM ) Revenue US$1.97m Cost of Revenue US$27.97m Gross Profit -US$26.00m Other Expenses US$1.12m Earnings -US$27.11m
Last Reported Earnings
Mar 31, 2024
Earnings per share (EPS) -9.48 Gross Margin -1,317.12% Net Profit Margin -1,373.61% Debt/Equity Ratio -39.5%
How did NXE0 perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/08/13 02:32 End of Day Share Price 2024/05/16 00:00 Earnings 2024/03/31 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Seelos Therapeutics, Inc. is covered by 6 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Bruce Jackson Benchmark Company Mayank Mamtani B. Riley Securities, Inc. Thomas Shrader BTIG
Show 3 more analysts 
